1
|
van de Burgwal L, van der Valk T, Kempter H, Gadau M, Stubbs D, Boon W. An elephant in the glasshouse? Trade-offs between acceleration and transformation in COVID-19 vaccine innovation policies. ENVIRONMENTAL INNOVATION AND SOCIETAL TRANSITIONS 2023; 48:100736. [PMID: 37250374 PMCID: PMC10208527 DOI: 10.1016/j.eist.2023.100736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/29/2022] [Revised: 05/06/2023] [Accepted: 05/14/2023] [Indexed: 05/31/2023]
Abstract
Against the backdrop of a failing vaccine innovation system, innovation policy aimed at creating a COVID-19 vaccine was surprisingly fast and effective. This paper analyzes the influence of the COVID-19 landscape shock and corresponding innovation policy responses on the existing vaccine innovation system. We use document analysis and expert interviews, performed during vaccine development. We find that the sharing of responsibility between public and private actors on various geographical levels, and the focus on accelerating changes in the innovation system were instrumental in achieving fast results. Simultaneously, the acceleration exacerbated existing societal innovation barriers, such as vaccine hesitancy, health inequity, and contested privatization of earnings. Going forward, these innovation barriers may limit the legitimacy of the vaccine innovation system and reduce pandemic preparedness. Next to a focus on acceleration, transformative innovation policies for achieving sustainable pandemic preparedness are still urgently needed. Implications for mission-oriented innovation policy are discussed.
Collapse
Affiliation(s)
- Linda van de Burgwal
- Athena Institute, Vrije Universiteit, De Boelelaan 1085, Amsterdam, 1081 HV, the Netherlands
| | - Tom van der Valk
- Athena Institute, Vrije Universiteit, De Boelelaan 1085, Amsterdam, 1081 HV, the Netherlands
- Raymond James Corporate Finance, Health Care, London, United Kingdom
| | - Hannes Kempter
- Raymond James Corporate Finance, Health Care, London, United Kingdom
| | - Manuel Gadau
- Raymond James Corporate Finance, Health Care, London, United Kingdom
| | - David Stubbs
- Raymond James Corporate Finance, Health Care, London, United Kingdom
| | - Wouter Boon
- Copernicus Institute, Utrecht University, Utrecht, the Netherlands
| |
Collapse
|
2
|
Fialho BC, Gauss L, Soares PF, Medeiros MZ, Lacerda DP. Vaccine Innovation Meta-Model for Pandemic Contexts. J Pharm Innov 2023; 18:1-49. [PMID: 36818394 PMCID: PMC9924881 DOI: 10.1007/s12247-023-09708-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/03/2023] [Indexed: 02/16/2023]
Abstract
Purpose Over the past decade, successive outbreaks and epidemics of infectious diseases have challenged the emergency preparedness and response systems of global public health institutions, a context in which vaccines have become the centerpiece to strengthening global health security. Nevertheless, vaccine research and development (R&D) is a complex, lengthy, risky, uncertain, and expensive process. Alongside strict, time-consuming regulatory compliance, it takes multiple candidates and many years to register a new vaccine. This is certainly not welcome in a global health crisis such as the COVID-19 pandemic. Therefore, this study aims to understand the R&D paradigm shift in pandemic contexts and its impacts on the value chain of vaccine innovation. Methods To that end, this paper carried out a systematic literature review and meta-synthesis of 27 articles and reports (2011-2021) that addressed vaccine R&D in contexts of global health threats, disease outbreaks, epidemics, or pandemics. Results The research findings are synthesized in a meta-model, which describes a fast-track R&D for pandemic contexts, its driving forces, innovations, mechanisms, and impacts in the value chain of vaccine innovation. Conclusions The study demonstrates that, in pandemic contexts, a fast-track R&D process based on close collaboration among regulators, industry, and academia and leveraging enabling technologies can drastically reduce the time required to bring safe, stable, and effective vaccines to market by an average of 11 years compared to the traditional R&D process. Furthermore, pharmacovigilance and rigorous monitoring of real-world evidence became critical to ensuring that quality and safe products were authorized for use during a pandemic.
Collapse
Affiliation(s)
- Beatriz C. Fialho
- Bio-Manguinhos/Fiocruz Immunobiological Technology Institute, Rio de Janeiro, RJ Brazil
| | - Leandro Gauss
- Production and Systems Engineering Graduate Program, Unisinos, São Leopoldo, RS Brazil
| | - Priscila F. Soares
- Bio-Manguinhos/Fiocruz Immunobiological Technology Institute, Rio de Janeiro, RJ Brazil
| | - Maurício Z. Medeiros
- Bio-Manguinhos/Fiocruz Immunobiological Technology Institute, Rio de Janeiro, RJ Brazil
| | - Daniel P. Lacerda
- Production and Systems Engineering Graduate Program, Unisinos, São Leopoldo, RS Brazil
| |
Collapse
|
3
|
Janse M, Soekhradj SD, de Jong R, van de Burgwal LHM. Identifying Cross-Utilization of RSV Vaccine Inventions across the Human and Veterinary Field. Pathogens 2022; 12:pathogens12010046. [PMID: 36678394 PMCID: PMC9865526 DOI: 10.3390/pathogens12010046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Revised: 12/23/2022] [Accepted: 12/24/2022] [Indexed: 12/30/2022] Open
Abstract
The respiratory syncytial virus (RSV) has two main variants with similar impact, a human and a bovine variant. The human respiratory syncytial virus (HRSV) is the most frequent cause of acute respiratory disease (pneumonia) in children, leading to hospitalization and causing premature death. In Europe, lower respiratory tract infections caused by HRSV are responsible for 42-45 percent of hospital admissions in children under two. Likewise, the bovine respiratory syncytial virus (BRSV) is a significant cause of acute viral broncho-pneumonia in calves. To date no licensed HRSV vaccine has been developed, despite the high burden of the disease. In contrast, BRSV vaccines have been on the market since the 1970s, but there is still an articulated unmet need for improved BRSV vaccines with greater efficacy. HRSV/BRSV vaccine development was chosen as a case to assess whether collaboration and knowledge-sharing between human and veterinary fields is taking place, benefiting the development of new vaccines in both fields. The genetic relatedness, comparable pathogeneses, and similar severity of the diseases suggests much can be gained by sharing knowledge and experiences between the human and veterinary fields. We analyzed patent data, as most of pharmaceutical inventions, such as the development of vaccines, are protected by patents. Our results show only little cross-utilization of inventions and no collaborations, as in shared IP as an exchange of knowledge. This suggests that, despite the similarities in the genetics and antigenicity of HRSV and BRSV, each fields follows its own process in developing new vaccines.
Collapse
Affiliation(s)
- Marga Janse
- Athena Institute, Faculteit der Bètawetenschappen W&N Gebouw, VU Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
- Correspondence:
| | - Swasti D. Soekhradj
- Athena Institute, Faculteit der Bètawetenschappen W&N Gebouw, VU Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
| | - Rineke de Jong
- Wageningen Bioveterinary Research, Houtribweg 39, 8221 RA Lelystad, The Netherlands
| | - Linda H. M. van de Burgwal
- Athena Institute, Faculteit der Bètawetenschappen W&N Gebouw, VU Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
| |
Collapse
|
4
|
A Review of Lean Methodology Application and Its Integration in Medical Device New Product Introduction Processes. Processes (Basel) 2022. [DOI: 10.3390/pr10102005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The purpose of this study is to review the Lean tool application and its utilisation in medical device design and the new product introduction process to establish the benefits and best practices for its integration with existing new product introduction processes. A review of the literature on the current state of medical device New Product Introduction (NPI) processes is completed along with a comprehensive review of the literature on the history and development of Lean NPI. The review indicates that Lean can be combined with the predominant NPI execution tools, Stage-Gate and Concurrent Engineering within the medical device industry to achieve a best-in-class continuous improvement methodology within the NPI process. This integration eliminates waste, focusses on customer value, and ultimately reduces cost and lead time to market. This review highlights for the first time the main challenges and issues with Lean in the medical device sector NPI processes, identifying possible future strands of research. Limitations of the current review are that despite the heavy emphasis placed on Lean manufacturing processes, comparatively little emphasis is placed on the use of Lean in the medical device NPI process. Future longitudinal case studies on case study application of Lean in medical device NPI processes would be useful. This study has implications for identifying best practices for Lean in NPI in the device industry, improving what is considered state-of-the-art for the introduction of devices into the public domain.
Collapse
|
5
|
Medeiros MZ, Soares PF, Fialho BC, Gauss L, Piran FS, Lacerda DP. Vaccine innovation model: A technology transfer perspective in pandemic contexts. Vaccine 2022; 40:4748-4763. [PMID: 35773123 PMCID: PMC9236274 DOI: 10.1016/j.vaccine.2022.06.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 06/08/2022] [Accepted: 06/20/2022] [Indexed: 12/04/2022]
Abstract
This work identifies the innovations that made it possible for the Bio-Manguinhos/Fiocruz Immunobiological Technology Institute to engage in the entire production of the Oxford/AstraZeneca vaccine (ChAdOx1 nCov-19) in Brazil, just 1.8 years after the COVID-19 pandemic was declared. The results were summarized in a case-based innovation model composed of 11 workstreams, 32 stages, 22 gates, 11 innovations, and 38 events. In terms of research contributions, three were found: (i) the identification of firm and government-level innovations allowing the substantial reduction in the COVID-19 vaccine time-to-market in Brazil; (ii) the presentation of empirical evidence supporting the new Outbreak Paradigm for vaccine research, development, and production; and (iii) the proposition of a conceptual model for describing innovations through the vaccine value chain in pandemic contexts, particularly when technology transfer is involved.
Collapse
Affiliation(s)
- Maurício Z Medeiros
- Bio-Manguinhos/Fiocruz Immunobiological Technology Institute, Rio de Janeiro, RJ, Brazil
| | - Priscila F Soares
- Bio-Manguinhos/Fiocruz Immunobiological Technology Institute, Rio de Janeiro, RJ, Brazil
| | - Beatriz C Fialho
- Bio-Manguinhos/Fiocruz Immunobiological Technology Institute, Rio de Janeiro, RJ, Brazil
| | - Leandro Gauss
- Production and Systems Engineering Graduate Program, Unisinos, São Leopoldo, RS, Brazil.
| | - Fábio S Piran
- Production and Systems Engineering Graduate Program, Unisinos, São Leopoldo, RS, Brazil
| | - Daniel P Lacerda
- Production and Systems Engineering Graduate Program, Unisinos, São Leopoldo, RS, Brazil
| |
Collapse
|
6
|
Janse M, Brouwers T, Claassen E, Hermans P, van de Burgwal L. Barriers Influencing Vaccine Development Timelines, Identification, Causal Analysis, and Prioritization of Key Barriers by KOLs in General and Covid-19 Vaccine R&D. Front Public Health 2021; 9:612541. [PMID: 33959579 PMCID: PMC8096063 DOI: 10.3389/fpubh.2021.612541] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Accepted: 03/23/2021] [Indexed: 11/13/2022] Open
Abstract
A frequently mentioned factor holding back the introduction of new vaccines on the market are their prohibitively long development timelines. These hamper their potential societal benefit and impairs the ability to quickly respond to emerging new pathogens. This is especially worrisome since new pathogens are emerging at all-time high rates of over one per year, and many age-old pathogens are still not vaccine preventable.Through interviews with 20 key-opinion-leaders (KOLs), this study identified innovation barriers that increase vaccine development timelines. These innovation barriers were visualized, and their underlying causes revealed by means of qualitative root cause analysis. Based on a survey the innovation barriers were quantitatively ranked based on their relative impact on both regular, and Covid-19 vaccine development timelines. KOLs identified 20 key innovation barriers, and mapping these barriers onto the Vaccine Innovation Cycle model revealed that all phases of vaccine development were affected. Affected by most barriers is the area between the preclinical studies and the market entry. Difficult hand-off between academia and industry, lack of funding, and lack of knowledge of pathogen targets were often mentioned as causes. Quantitative survey responses from 93 KOLs showed that general vaccine development and Covid-19 vaccine development are impacted by distinct sets of innovation barriers. For the general vaccine development three barriers were perceived of the highest impact; limited ROI for vaccines addressing disease with limited market size, limited ROI for vaccines compared to non-vaccine projects, and academia not being able to progress beyond proof of principle. Of highest impact on Covid-19 vaccine development, are lack of knowledge concerning pathogen target, high risk of upscaling unlicensed vaccines, and proof of principle not meeting late-stage requirements. In conclusion, the current study demonstrates that barriers hampering timelines in vaccine development are present across the Vaccine Innovation Cycle. Prioritizing the impact of barriers in general, and in Covid-19 vaccine development, shows clear differences that can be used to inform policies to speed up development in both war and peace time.
Collapse
Affiliation(s)
- Marga Janse
- Athena Institute, Faculty of Earth and Life Sciences, Vrije Universiteit, Amsterdam, Netherlands
| | - Thomas Brouwers
- Athena Institute, Faculty of Earth and Life Sciences, Vrije Universiteit, Amsterdam, Netherlands
| | - Eric Claassen
- Athena Institute, Faculty of Earth and Life Sciences, Vrije Universiteit, Amsterdam, Netherlands
| | - Peter Hermans
- Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht (UMCU), Utrecht, Netherlands
| | - Linda van de Burgwal
- Athena Institute, Faculty of Earth and Life Sciences, Vrije Universiteit, Amsterdam, Netherlands
| |
Collapse
|
7
|
|